Freestone Grove Partners LP Biomarin Pharmaceutical Inc Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 476,436 shares of BMRN stock, worth $26.1 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
476,436
Previous 335,513
42.0%
Holding current value
$26.1 Million
Previous $18.4 Billion
39.91%
% of portfolio
0.19%
Previous 0.14%
Shares
2 transactions
Others Institutions Holding BMRN
# of Institutions
669Shares Held
182MCall Options Held
1.52MPut Options Held
1.01M-
Black Rock Inc. New York, NY22.7MShares$1.24 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.6MShares$1.02 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA15.2MShares$833 Million0.65% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$804 Million0.46% of portfolio
-
State Street Corp Boston, MA8.76MShares$480 Million0.02% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.2B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...